INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2007

Oral resveratrol was safe up to 5 g, but peak plasma levels were lower than concentrations typically required for in vitro cancer chemopreventive effects.

A phase I study evaluated single oral doses of resveratrol (0.5, 1, 2.5, or 5 g) in 10 healthy volunteers per dose level. Administration did not cause serious adverse events. Peak plasma levels of resveratrol at the 5 g dose were 539 +/- 384 ng/mL (2.4 micromol/L), occurring 1.5 hours post-dose, while peak levels of metabolites were 3- to 8-fold higher. The authors note that because in vitro cancer chemopreventive effects require at least 5 micromol/L, high-dose resveratrol might be insufficient to elicit systemic levels commensurate with efficacy, though conjugate metabolites warrant investigation.

Study type
Phase I dose escalation pharmacokinetic study
Who was studied
40 healthy volunteers (10 per dose level)
What was measured
Safety and plasma and urine pharmacokinetics of resveratrol and its metabolites

THE PAPER

Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.

Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE. Cancer Epidemiol Biomarkers Prev, 2007.

PubMed 17548692 ↗DOI 10.1158/1055-9965.epi-07-0022 ↗

CancerNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.